All News

The Food and Drug Administration approved Keytruda (pembrolizumab) for the treatment of certain patients with cervical cancer.

In a presentation at the 2018 ASCO Annual Meeting, researchers from Kaiser Permanente also found that women were almost twice as likely to die from the disease compared with non-cancer deaths.

Breast cancer survivor grieves the loss of her mom to metastatic breast cancer and considers how she keeps deceased loved ones in her heart.

A male breast cancer survivor shares his most important tip.

The Food and Drug Administration (FDA) approved the supplemental New Drug Application to add to the U.S. Prescribing Information for Kyprolis (carfilzomib) for the treatment of patients with relapsed or refractory multiple myeloma.

How I escaped from cancer as a kid.

The FDA approved the Paxman Scalp Cooling System for patients with solid tumors who wish to prevent chemotherapy-related hair loss.

Part one of a three part series about my experiences about Relay for Life 2018

Being a survivor and patient advocate means keeping up to date with the latest in treatment options and hearing the latest news in cancer research. ASCO is the perfect conference for just that.

The survey contained questions on a range of issues they may have experienced, including pain, fatigue, as well as issues with sexual function, body image and finances. Researchers then looked at the anxiety and depression associated with those issues, and talked with patients about what they thought might be causing those problems.

Recognize birthdays, but most importantly, keep hope, says a breast cancer and melanoma survivor.

What are important considerations for hurricane preparedness when undergoing cancer treatment?

A breast cancer survivor's thoughts on her eight-year cancerversary.

My research revealed some surprising findings. What can we do to fix this?

Cancer affects many aspects of a person’s life, such as the overall quality of their day-to-day living, but what if a person didn’t have the full-blown disease already? Could a precursor or asymptomatic stage of the disease still burden them?

None of us are perfect. We all have flaws and imperfections, some us more than others.

The Food and Drug Administration (FDA) approved Venclexta (venetoclax) in combination with Rituxan (rituximab) for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without the genetic mutation 17p deletion, who have received at least one prior therapy.

How not being a writer and still writing helped me through cancer and cancer treatment.

What do you do? What should you know? Here are some practical pieces of advice from someone who

If approved, it will become the second PARP inhibitor in the breast cancer space.

Racial disparities in palliative and hospice care beliefs appear to influence early integration in to standard oncologic care for patients with advanced lung cancer.

The ways life hits us with various challenges is neither fair nor fun, but we can still find happiness.

An expert from Texas Oncology offers perspective on findings from the CCGA study – presented at the 2018 ASCO Annual Meeting – which may support the use of a blood test to detect lung cancer earlier.

It was the drop heard 'round the colorectal cancer world.

How skateboarding helped get me through cancer treatment at age 11.

A cancer veteran lists ten things that ought to be a part of this nation's public health education.

Under Medicare’s new oncology care model, patient-centric treatment aims to save money while improving health outcomes.

The Food and Drug Administration (FDA) approved Leukine (sargramostim) for the treatment of adult and pediatric patients who are exposed to myelosuppressive doses of radiation that results in a hematopoietic subsyndrome of acute radiation syndrome.

Every survivor has a story about our disease, and what we choose to believe can change everything.

Although genetic testing could be crucial in developing treatment plans and improving outcomes in women with ovarian and breast cancer, less than 20 percent of eligible patients actually get tested, according to Mike Janicek, M.D.